Nutriband Inc. (NTRB) Stock Price & Analysis

Nutriband Inc. (NTRB) rose 1.76% to USD 6.08 as of September 8, 2026 at 16:48 UTC, according to Nexqual real-time market data.

NTRB last closed at USD 6.08; the session ranged USD 5.46–6.47 on volume of 57,747 shares. Market capitalization is —, with a 52-week range of USD 2.8–8.63 (NCM). Source: Nexqual, September 8, 2026 at 16:48 UTC.

Key Statistics (as of September 8, 2026 at 16:48 UTC)

Technical Analysis (NTRB)

Nexqual's technical model rates NTRB "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of September 8, 2026 at 16:48 UTC.

From Nutriband Inc.'s Latest SEC 10-K Filing (filed 2026-04-29)

Key Strengths & Strategy (as disclosed to the SEC)

• Each country may require that additional clinical and nonclinical studies be conducted prior to approval.   The process required by the FDA to receive approval prior to marketing and distributing a drug in the United States generally involves a preclinical phase followed by three phases of clinical trials which culminates in a New Drug Application (NDA) to the FDA for approval.
• Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product.   The purpose of the meeting was to specifically provide feedback on the Chemistry, Manufacturing, and Controls (CMC) plans for the product from submission of an Investigational New Drug Application (IND) through approval of a 505(b)(2) New Drug Application (NDA).
• Our development pipeline primarily consists of transdermal products that are based on our proprietary AVERSA ™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.   The Company's revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics.
• We are looking to utilize our proprietary approach to incorporate aversive agents into the transdermal patch to deter the abuse of fentanyl patches by the oral, buccal and inhaled routes, which represent as much as 70% of all transdermal fentanyl abuse.

Partnerships

• Failure to fully disclose or not in time reporting could lead to penalties up to $1.15 million per year.   The manufacturing of any of our products will be required to comply with the FDA's current Good Manufacturing Practices (cGMP) regulations.
• Our lead product is AVERSA™ Fentanyl for which we have a commercial development agreement with Kindeva Drug Delivery, a contract development and manufacturing organization.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 16:48 UTC. This page is informational and not investment advice.